Market revenue in 2021 | USD 4,650.8 million |
Market revenue in 2030 | USD 7,362.4 million |
Growth rate | 5.2% (CAGR from 2021 to 2030) |
Largest segment | Mammalian |
Fastest growing segment | Mammalian |
Historical data | 2017 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Mammalian, Non-mammalian |
Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 62.84% in 2021. Horizon Databook has segmented the Germany biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.
Germany biopharmaceutical CMO & CRO market is an attractive destination for many contract manufacturing cooperation partners. It offers services ranging from initial product idea to the final product at moderate cost for both national and international clients.
For instance, Boehringer Ingelheim is recognized as the company that is active across the entire biopharmaceutical process chain. These factors help clients with faster timelines and simpler coordination of process across the world.
Presence of Federal Ministry for Economic Affairs and Energy, which is involved in undertaking initiatives such as “Health-Made in Germany” to identify possible partners for contract manufacturing, is anticipated to drive the market growth. Furthermore, “German Bio Manufacturing Guide” helps clients by providing a comprehensive overview of biomanufacturing companies that are currently active in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany biopharmaceutical cmo and cro market , including forecasts for subscribers. This country databook contains high-level insights into Germany biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account